肺癌筛查CT上偶然发现的肾上腺结节
回顾性分析2015年1月至2023年8月本医疗系统内所有肺癌筛查CT,纳入191例报告了局灶性肾上腺结节并使用Lung-RADS「S」修饰符的病例,评估随访影像和生化检查推荐与执行对ACR指南的依从性。结果显示按ACR推荐应随访的36例中仅23例(64%)获得随访推荐,而155例无需随访者中25例(16%)被推荐随访;应接受生化检查的183例中仅4例(2%)被推荐。作者认为对肺癌筛查CT偶然肾上腺结节的管理对ACR指南依从性欠佳,存在不必要和遗漏的随访推荐。
要点
- 肺癌筛查CT报告局灶性肾上腺结节时应使用Lung-RADS「S」修饰符,并按ACR指南判断是否需要随访及生化检查。
- 本研究中按ACR应随访的36例仅64%获随访推荐,而无需随访的155例中16%被过度推荐随访。
- 按ACR应行生化检查的183例中仅2%被推荐,生化检查推荐几乎缺失。
核心结论
- 对肺癌筛查CT偶然发现的肾上腺病变,对ACR指南的依从性欠佳,同时存在不必要的和遗漏的随访推荐。
- 生化检查的推荐几乎不存在,尽管它是ACR流程的一部分。
- 本研究未诊断任何恶性病变。
研究设计与样本
- 回顾性分析本医疗系统内2015年1月至2023年8月所有肺癌筛查CT检查。
- 纳入报告了局灶性肾上腺结节并使用Lung-RADS「S」修饰符的CT,共191例患者。
- 记录是否推荐并执行了随访影像和生化检查,并评估报告中的随访推荐对ACR指南的依从性。
诊断标准与关键数值
- 按ACR推荐,191例中36例(19%)需要随访,但其中仅23例(64%)获得了随访推荐。
- 191例中155例(81%)按ACR无需随访,但其中25例(16%)获得了随访推荐。
- 在获得随访建议的48例中,34例(71%)接受了专门随访,9例(19%)因其他原因接受了随访影像,5例(10%)未接受任何随访。
- 在未被推荐随访的143例中,21例(15%)接受了专门随访,101例(71%)因其他原因接受了随访影像,21例(15%)未接受任何随访。
- 按ACR推荐,191例中183例(96%)应接受生化检查,但仅4例(2%)被推荐。
临床应用与阅片要点
- 报告肺癌筛查CT肾上腺结节时,应使用Lung-RADS「S」修饰符并依据ACR指南判断随访和生化检查需求。
- 注意避免对无需随访的肾上腺结节过度推荐随访,同时避免遗漏需要随访的病例。
- 生化检查是ACR肾上腺病变管理流程的组成部分,报告中应评估并推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess adherence to ACR recommendations for managing incidental adrenal lesions detected on lung cancer screening (LCS) CT examinations.
METHODS: We performed a retrospective analysis of all LCS CT examinations within our health care system from January 2015 to August 2023. We included CTs that were reported with Lung-RADS "S" modifier for a focal adrenal lesion. We recorded whether follow-up imaging and biochemical testing were recommended and whether they were performed. Follow-up recommendations in reports were assessed for adherence to ACR recommendations.
RESULTS: During the study period, 191 patients had a focal adrenal nodule reported. Per ACR recommendations, 36 of 191 (19%) warranted follow-up, but only 23 of 36 (64%) of these received follow-up recommendations. Of those 191, 155 (81%) did not require follow-up per ACR, and 25 of those 155 (16%) received follow-up recommendations. Of those who were advised follow-up, 34 of 48 (71%) received dedicated follow-up, 9 of 48 (19%) received follow-up imaging for another reason, and 5 of 48 (10%) did not receive any follow-up. Among those in whom follow-up was not recommended, 21 of 143 (15%) received dedicated follow-up, 101 of 143 (71%) received follow-up imaging for another reason, and 21 of 143 (15%) did not receive any follow-up. No malignant lesions were diagnosed. Per ACR recommendations, 183 of 191 (96%) of patients should have received biochemical testing; however, it was recommended in only 4 patients (2%).
DISCUSSION: There was suboptimal adherence to ACR recommendations for managing incidental adrenal lesions on LCS CTs, with both unnecessary and missing follow-up recommendations. Recommendations for biochemical testing were nearly nonexistent, despite being part of the ACR algorithm.
引用
- Singh A, Hammer MM, Byrne SC, et al. Incidentally Detected Adrenal Nodules on Lung Cancer Screening CT. J Am Coll Radiol. 2025. PMID: 40044307. doi:10.1016/j.jacr.2024.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。